The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.

Leukemia
Felicitas La RoséePaul La Rosée

Abstract

A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th, 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by ≥25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-interventi...Continue Reading

Associated Clinical Trials

Apr 8, 2020·Prof. Dr. med. Andreas Hochhaus

References

Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Jul 4, 2017·Journal of Autoimmunity·Federico Lussana, Alessandro Rambaldi
Aug 31, 2019·British Journal of Haematology·Emanuela Sant'AntonioElisa Rumi
Sep 14, 2019·Haematologica·Jingshi WangZhao Wang
Feb 23, 2020·The Lancet. Respiratory Medicine·Zhe XuFu-Sheng Wang
Mar 19, 2020·The New England Journal of Medicine·Bin CaoChen Wang
Mar 21, 2020·Lancet·Puja MehtaUNKNOWN HLH Across Speciality Collaboration, UK
Mar 21, 2020·The Journal of Antimicrobial Chemotherapy·Dan ZhouQiang Tong
Mar 29, 2020·The Journal of Clinical Investigation·Guang ChenQin Ning
Mar 31, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Wen ZhangShuyang Zhang
Apr 1, 2020·The New England Journal of Medicine·Pavan K BhatrajuCarmen Mikacenic
Apr 3, 2020·Nature·Roman WölfelClemens Wendtner
Apr 11, 2020·The New England Journal of Medicine·Jonathan GreinTimothy Flanigan
Apr 19, 2020·Science·John B Moore, Carl H June
Apr 19, 2020·The Lancet. Respiratory Medicine·Fabio S TacconeJean-Louis Vincent
Apr 19, 2020·Chest·Ruchong ChenUNKNOWN Medical Treatment Expert Group for COVID-19
Apr 23, 2020·The New England Journal of Medicine·Robert ZeiserUNKNOWN REACH2 Trial Group
Apr 26, 2020·The Journal of Infection·Fabrizio CantiniDelia Goletti
May 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Xiaoling XuHaiming Wei

❮ Previous
Next ❯

Citations

Jun 28, 2020·European Journal of Haematology·Steffen KoschmiederMichael Dreher
Sep 6, 2020·Pharmacological Reports : PR·Thakur Uttam SinghRaj Kumar Singh
Sep 15, 2020·Advanced Materials·Meng QinYunfeng Lu
Sep 24, 2020·Advances in Rheumatology·Bruno BordalloMarcelo Pinheiro
Aug 21, 2020·Leukemia·Alessandro M VannucchiUNKNOWN RUXO-COVID Study Group
Sep 19, 2020·Cancer Medicine·Douglas TremblayUNKNOWN Mount Sinai Health System Convalescent Plasma Team
Jul 29, 2020·International Urology and Nephrology·Gianluigi TavernaFabio Grizzi
Sep 4, 2020·Leukemia·Alessandro GozzettiMonica Bocchia
Nov 28, 2020·Postgraduate Medicine·Sairaj SatarkerMadhavan Nampoothiri
Aug 17, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Boghuma K TitanjiVincent C Marconi
Dec 22, 2020·Expert Opinion on Pharmacotherapy·Iwona HusTadeusz Robak
Dec 29, 2020·Journal of Biomolecular Structure & Dynamics·Julián F Fernández, Martín J Lavecchia
Nov 21, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Vladislav IzdaAmr H Sawalha
Jan 27, 2021·Infectious Diseases and Therapy·Nicholas ReboldMichael Rybak
Jan 26, 2021·Frontiers in Oncology·Cirino BottaFrancesco Mendicino
Feb 5, 2021·Journal of Medicinal Chemistry·Rinky Raghuvanshi, Sandip B Bharate
Feb 9, 2021·Journal of Ovarian Research·Antonio MacciòClelia Madeddu
Feb 4, 2021·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Visesha KakarlaJason D Hinman
Jan 30, 2021·Frontiers in Physiology·Varnica BajajVaishali R Moulton
Nov 17, 2020·Frontiers in Immunology·Howard M JohnsonChulbul M Ahmed
Dec 11, 2020·Nature Communications·Niyati DesaiVikram Deshpande
Feb 15, 2021·Pulmonology·M PolastriF Tagariello
Oct 29, 2020·Medizinische Klinik, Intensivmedizin und Notfallmedizin·P La RoséeS Russo
Oct 28, 2020·Leukemia·Baransel Kamaz, Ann Mullally
Nov 27, 2020·Drug Design, Development and Therapy·Nicholas BorcherdingPraveen Vikas
Oct 18, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicola GiesenMarie von Lilienfeld-Toal
Mar 1, 2021·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Shukur Wasman SmailMuhammad Safdar
Mar 13, 2021·Frontiers in Pharmacology·Angela E PeterV Lakshmi Kalpana
Mar 19, 2021·Leukemia·Marko Lucijanic, Rajko Kusec
Mar 18, 2021·Immune Network·Erica EspañoJeong-Ki Kim

❮ Previous
Next ❯

Methods Mentioned

BETA
blood drawing

Clinical Trials Mentioned

NCT04338958
NCT04362137
NCT04359290
NCT04331665

Software Mentioned

board
MS Excel

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

© 2022 Meta ULC. All rights reserved